Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07534475

Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT

Conditions: Major Depressive Disorder, Bipolar Disorder, Schizophrenia

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: NA
Enrollment: 20
Sponsor: Medipol University

Location: Istanbul Medipol University Istanbul

Summary

This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring motor seizure activity during Electroconvulsive Therapy (ECT). Using a within-subject (intra-individual) design, each of the 40 enrolled patients will receive an arterial tourniquet on one arm and a venous tourniquet on the other arm simultaneously. The study will evaluate clinical efficacy in observing motor seizures, comparing the duration and visibility between the two limbs of the same patient, as well as assessing overall patient comfort and hemodynamics.

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for elective Electroconvulsive Therapy (ECT). * ASA (American Society of Anesthesiologists) physical status I to III. Exclusion Criteria: * Known neuromuscular diseases (e.g., Myasthenia Gravis). * Known allergy or hypersensitivity to sugammadex, rocuronium, ketamine, dexmedetomidine, or propofol. * Presence of venous insufficiency, lymphedema, or active infection in the upper extremities. * Severe cardiovascular instability.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07534475). StuddyBuddy aggregates publicly available trial information.